Beta-amyloid (Aβ) peptides derived from amyloid precursor protein are found in human cerebrospinal fluid (CSF) and have proven to be informative biomarkers with respect to neurodegeneration, especially Alzheimer’s disease (AD). Quantification of A&beta peptides has proven useful in discriminating AD from other dementias and in staging AD patients with respect to the natural progression of the disease. The Aβ40 Peptide (4G8) Kit provides a sensitive and efficient means to monitor changes in concentrations of Aβ40 peptide and has been validated for measurement in human CSF and mouse plasma. This assay is also compatible with other sample types, including conditioned neuronal cell culture medium, cell lysates, and tissue homogenates such as mouse brain. The kit was developed according to “fit for purpose” principles and is consistent with guidance from the Clinical and Laboratory Standards Institute. The validated assay uses an Aβ40-specific capture antibody with an anti-beta amyloid (17-24) antibody (4G8 clone) as the detection antibody. The 4G8 clone is provided by Covance Research Products, Inc.
-
-
Specifications
-
Kit Contents
-
References
-
Documentation
Application(s)
|
|
Alzheimer’s Disease
,
Neurobiology/Neurodegen.
|
|
Analyte(s)
|
|
Aβ40
|
|
Species
|
|
Human, Mouse, Rat
|
|
Instrument
|
|
MESO QuickPlex SQ 120
,
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO SECTOR S 600
|
|
Plate Type
|
|
96-well
|
|
Capture Antibody
|
|
Mouse Monoclonal
|
|
Detection Antibody
|
|
Mouse Monoclonal
|
|
Dynamic Range
|
|
5.41-6000 pg/mL
|
|
Sample Type
|
|
Rodent Serum, Rodent Plasma, Cell Culture Supernatant, Tissue Homogenate, CSF
|
|
Recombinant standards
|
|
Synthetic Aβ peptides
|
|
LLOD (Sensitivity)
|
|
5.41 pg/mL
|
|
LLOQ (Sensitivity)
|
|
20 pg/mL
|
|
ULOQ (Sensitivity)
|
|
6000 pg/mL
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Diluent Assembly 9
|
≤-10°C
|
1 ea
|
|
Neurodegeneration Control 1
|
≤-70°C
|
1 vial
|
|
Neurodegeneration Control 2
|
≤-70°C
|
1 vial
|
|
Neurodegeneration Control 3
|
≤-70°C
|
1 vial
|
|
|
≤-70°C
|
1 vial (30 μL)
|
|
|
2-8°C
|
1 vial (75 μL)
|
|
Aβ40 Peptide Plate
|
2-8°C
|
1 ea (1 ea)
|
|
|
2-8°C
|
1 ea (50 mL)
|
|
Diluent Assembly 9
|
≤-10°C
|
1 ea (NA ea)
|
|
|
RT
|
1 ea (100 mL)
|
|
|
RT
|
1 ea (50 mL)
|
|
|
2-8°C
|
1 ea (40 μL)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Diluent Assembly 10
|
≤-10°C
|
1 ea
|
|
Neurodegeneration Control 1
|
≤-70°C
|
5 vial
|
|
Neurodegeneration Control 2
|
≤-70°C
|
5 vial
|
|
Neurodegeneration Control 3
|
≤-70°C
|
5 vial
|
|
|
≤-70°C
|
5 vial (30 μL)
|
|
|
2-8°C
|
1 vial (375 μL)
|
|
Aβ40 Peptide Plate
|
2-8°C
|
5 ea (1 ea)
|
|
|
2-8°C
|
1 ea (50 mL)
|
|
Diluent Assembly 10
|
≤-10°C
|
1 ea (NA ea)
|
|
|
RT
|
1 ea (100 mL)
|
|
|
RT
|
1 ea (50 mL)
|
|
|
2-8°C
|
1 ea (200 μL)
|
|
Product Description
|
Storage
|
Quantity per Kit
|
Diluent Assembly 10
|
≤-10°C
|
5 ea
|
|
Neurodegeneration Control 1
|
≤-70°C
|
25 vial
|
|
Neurodegeneration Control 2
|
≤-70°C
|
25 vial
|
|
Neurodegeneration Control 3
|
≤-70°C
|
25 vial
|
|
|
≤-70°C
|
25 vial (30 μL)
|
|
|
2-8°C
|
5 vial (375 μL)
|
|
Aβ40 Peptide Plate
|
2-8°C
|
25 ea (1 ea)
|
|
|
2-8°C
|
5 ea (50 mL)
|
|
Diluent Assembly 10
|
≤-10°C
|
5 ea (NA ea)
|
|
|
RT
|
5 ea (100 mL)
|
|
|
RT
|
5 ea (50 mL)
|
|
|
2-8°C
|
5 ea (200 μL)
|
|
Title
|
Journal
|
Year
|
|
A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.
|
|
|
|
Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren's syndrome.
|
|
|
|
Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.
|
|
|
|
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein.
|
|
|
|
Development and implementation of a high-throughput compound screening assay for targeting disrupted ER calcium homeostasis in Alzheimer's disease.
|
|
|
|
View All
|
Product Inserts
|
|
|
Product Highlights
|
|
|
Certificate of analysis
|
|
View More
|
SDS
|
|
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters